REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue ...

Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. ・The company ...

As of Friday, December 19, Cassava Sciences, Inc.’s SAVA share price has dipped by 17.37%, which has investors questioning if this is right time to buy.

KIEV, UKRAINE - 2019/01/16: In this photo illustration, the Edwards Lifesciences Medical device company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA ...

On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping ...

Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...

The biotech earned an important fast-track review designation from a major regulator. This should speed the development (and potentially, commercialization) of one of its investigational treatments.

An independent DSMB reviewed interim safety data for simufilam and recommended the trials proceed without modifications. Two ongoing trials with over 1,900 Alzheimer’s patients; top-line results from ...

The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...

Kodiak Sciences (KOD) has priced an expanded public offering of approximately 6.96 million shares at $23.00 each. The company expects to raise roughly $160 million in gross proceeds. Kodiak Sciences u ...